biogenex

BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of cancer of unknown primary (CUP) and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully automated molecular pathology work stations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life science research and diagnostics. With a team of accomplished technical, business and customer support professionals, BioGenex strives to reach the pinnacle of the global molecular medicine industry by offering cost-effective solutions for life sciences research and personalized medicine. Additionally, the partnership of BioGenex with top-notch universities, hospitals, and the pharmaceutical and biotechnology industry drives its innovative research and product development activities. The company is also known for its pre- and post-sales customer support that complements the high quality products and solutions offered by the firm.

Plasmidsaurus

We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. Sequence Everything!

biomakers

BIOMAKERS es Centro de Medicina Genómica de Precisión y Biotecnología especializado en Análisis genómicos, Big Data y desarrollo de Tecnología para Oncología y otras áreas terapéuticas complejas en Latinoamérica y USA . Cuenta con Laboratorios Moleculares propios integrados en Argentina, Mexico y Brasil, en donde se llevan a cabo estudios de biomarcadores asociados al diagnóstico genómico-molecular y una Oficina de Big Data & Technology en San Francisco, USA. BIOMAKERS prioriza la innovación a partir de la incorporación de nuevas tecnologías a través de su departamento de I+D, y el desarrollo de Plataformas Tecnológicas con Inteligencia Artificial, junto con el desarrollo e implementación de nuevos estudios genéticos para 17 países de Latinoamérica, habiendo construido el BIOBANCO de tumores avanzados y el Dataset para cáncer más importante y grande de Latino América. BIOMAKERS está conformada por profesionales con amplia trayectoria en el ámbito científico, médico, de investigación clínica, y de desarrollo de tecnología quienes cuentan con lun expertise único en la región y conforman el grupo más experto de LATAM en Medicina de Precisión. BIOMAKERS se compromete con la comunidad, a través de políticas de responsabilidad social empresaria (RSE). Desde su fundación ha comenzado a trazar esta trayectoria, a través de campañas de difusión y capacitación de diversos entes sociales (proveedores, clientes, comunidad en general), así como también programas específicos de estudios genéticos en la población latinoamericana.

Connect Biopharma

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD. With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com

Beta Bionics

Beta Bionics is a medical technology company focused on the design, development, and commercialization of the iLet Bionic Pancreas and the bihormonal configuration. The iLet is the first and only insulin delivery system that does not require carb counting*, bolusing, correction factors, or pre-set basal rates.  The only number needed to get started with the iLet Bionic Pancreas is a user’s weight – the iLet does the rest. The iLet lets users “Go Bionic” with their diabetes management. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation. *Users must be carb aware.